1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou...
Transcript of 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou...
![Page 1: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/1.jpg)
1
Motor systems II: The basal ganglia and Drugs
used for the treatment of Parkinson’s disease
Lou haiyanLou haiyan (娄海燕)(娄海燕)Institute of PharmacologyInstitute of Pharmacology
School of MedicineSchool of MedicineShandong UniversityShandong University
[email protected]@sdu.edu.cn
![Page 2: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/2.jpg)
2
Components of Basal Ganglia
![Page 3: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/3.jpg)
3
1. Components of Basal Ganglia
1. Caudate Nucleus 1. Caudate Nucleus (( 尾状核)尾状核)2. Putamen 2. Putamen (( 壳核)壳核)3.3.Globus Pallidus (GP)Globus Pallidus (GP) (苍白球,旧纹状体)(苍白球,旧纹状体)44. Substantia Nigra. Substantia Nigra (黑质)(黑质)
Pars CompactaPars Compacta (SNc) (SNc) (( 致密部)致密部) Pars Reticulata (SNr)Pars Reticulata (SNr) (网状部)(网状部)
55. Subthalamic Nucleus (STN) . Subthalamic Nucleus (STN) (( 丘脑底核)丘脑底核)
新纹状体纹状体
![Page 4: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/4.jpg)
4
2. Medium spiny neuron in striatum (MSN, 中型多棘神经元 )
1) MSN is the main efferent neurons in striatum;
2) MSN 的传入 :
Glu neurons in cortex
DA neurons in SNc
GABA neurons in striatum
Ach neurons in striatum
MSN 树突远端
MSN 胞体和树突近端
![Page 5: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/5.jpg)
5
3)MSN dendrite compose efferent system,
with GABA as the neurotransmitter. 4)Two types of DA receptors on MSN:D1 and D2-R:
D1-R : enhance direct pathway → GPi (苍白球内侧部)
D2-R : inhibit indirect pathway → GPe (苍白球外侧部)
![Page 6: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/6.jpg)
6
3.Circuit related with the Basal ganglia’s function in the control of movement
1) direct pathway (直接通路) :
在该通路 , 当新纹状体活动↑→皮层活动↑ ,
产生去抑制 (disinhibition) 现象
![Page 7: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/7.jpg)
7
2) indirect pathway ( 间接通路 ):
∵在该通路 , 新纹状体活动↑→皮层活动↓。 ∴此通路部分抵消直接通路对皮层的兴奋作用
![Page 8: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/8.jpg)
8
3) Substantia nigra-Neostriatum pathway ( 黑质 - 新纹状体通路 ): 此通路对上述两通路起调控作用。
DA 通过D1 受体增强直接通路,通过D2 抑制间接通路
![Page 9: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/9.jpg)
9
4.Diseases related with dysfunction of Basal ganglia
Parkinson disease Hutington’s disease (Chorea)
![Page 10: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/10.jpg)
10
A disease is mainly manifested by
extrapyramidal system motor dysfunction
because of degenerative disorder of CNS.
Parkinson’s Disease
![Page 11: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/11.jpg)
11
CNS degenerative disease
Alzheimer’s disease (AD, 阿尔茨海默病 )
Parkinson’s disease (PD, 帕金森病 ) Huntington disease (HD, 亨廷顿病 ) Amyotrophic lateral sclerosis (ALS,
肌萎缩侧索硬化症 )
![Page 12: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/12.jpg)
12
First described in 1817 by an English physician, James Parkinson, in “An Essay on the Shaking Palsy.”
“paralysis agitans” ( 震颤麻痹 )
Parkinson’s Disease History
James C. Parkinson
![Page 13: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/13.jpg)
13
The famous French neurologist, Charcot,
further described the syndrome in 1868
(rigidity)----named ”Parkinson disease”.
1919: 确定病变部位主要在黑质
1960: 发现与黑质纹状体中 DA 含量显著降低有关
Parkinson’s Disease History
![Page 14: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/14.jpg)
Muhammad Ali in Alanta OlympicMuhammad Ali in Alanta Olympic
Parkinson’s DiseaseParkinson’s Disease
Katharine Hepburn Michael·J·Fox
![Page 15: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/15.jpg)
15
Parkinson’s Disease (PD)-Symptoms
1. Resting tremor ( 静止震颤 )
2. Bradykinesia ( 运动迟缓 )
3. Rigidity ( 肌肉强直 )
4. Ataxia ( 共济失调 )
颤,硬,慢,共济失调
![Page 16: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/16.jpg)
16
5. Others Abnormality of posture and gait
Handwriting
Memory impairment, confusion,
disorientation
Cognitive deficits
Depression
Parkinson’s Disease (PD)-Symptoms
![Page 17: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/17.jpg)
17
![Page 18: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/18.jpg)
Presymptomatic phase
Onset
SleepOlfactory*MoodAutonomic system
Diagnosis
Early nonmotor symptoms Specific symptoms
Motor
PD symptoms
Dopaminergic neuron loss in PD
% R
emai
nin
g
% R
emai
nin
g
Do
pam
ine
rgic
Neu
ron
sD
op
amin
erg
ic N
euro
ns
Time (years)
Nonmotor
Adapted image reprinted from Neurotherapeutics, Vol. 6, Halperin I, Morelli M, Korczyn AD, Youdim MB, Mandel SA. Biomarkers for evaluation of clinical efficacy of multipotential neuroprotective drugs for Alzheimer's and Parkinson's diseases, pages 128-140, Copyright 2009, with permission from Elsevier.
*Olfactory dysfunction may predate clinical PD by at least 4 years.
Halperin et al. Neurotherapeutics. 2009;6:128-140.Lang. Neurology. 2007;68:948-952. Ross et al. Ann Neurol. 2008;63:167-173.
Halperin et al. Neurotherapeutics. 2009;6:128-140.Lang. Neurology. 2007;68:948-952. Ross et al. Ann Neurol. 2008;63:167-173.
![Page 19: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/19.jpg)
19
From 1997, April 11th was set as World Parkinson's Disease Day, in memory of the birthday of James Parkinson-- the doctor who described PD.
World Parkinson’s disease day
![Page 20: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/20.jpg)
20
Epidemiology of PD
The second most common neurodegenerative
disorder after Alzheimer’s disease (AD). Increase with age (1% population >65 years old) Mean age at onset: 60 years old
85% of patients are over 65 years old
![Page 21: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/21.jpg)
21
Classification
1.Primary PD : unknown
2.Secondary: Parkinsonism
Cerebral arteriosclerosis
Encephalitis( 脑炎 )
Drug poison( 药物中毒 ):氰化物、利舍平、
酚噻嗪类及抗抑郁药等Chemicals: Mn2+ 、除草剂、杀虫剂等
![Page 22: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/22.jpg)
22
Etiology of PD
Unknown:
Increasing age (rare in those < 50; early or young onset)
More often to occur in families with relatives with PD Alpha-synuclein/Parkin/LRRK2/DJ-1 etc
Environmental factors (pesticides, rural residence)
Head trauma? Infection?
Caffeine and smoking have been found to be protective
![Page 23: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/23.jpg)
23
Risk of Parkinson’s Disease
Increased risk Age High Body Mass Index Male gender Family history Depression Environment factors
rural living well-water drinking welding head injury
Decreased risk Caffeine intake Smoking cigarettes Anti-oxidants in diet
![Page 24: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/24.jpg)
24
Animal model of PD
MPTP 6-OHDA Rotenone Paraquat
![Page 25: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/25.jpg)
25
1. Dopamine (DA) theory
Pathophysiology
DA neuronal degeneration in
substantia nigra
reduced or lack of dopamine
in the striatum
![Page 26: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/26.jpg)
26
PD Pathology
Normal PD
substantia nigra substantia nigra
![Page 27: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/27.jpg)
27
Nigrosriaial Dopamine Pathway
![Page 28: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/28.jpg)
28
核
![Page 29: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/29.jpg)
29
当 DA合成减少或 DA神经元退化时
传入
传出
白质背侧
腹侧ACh兴奋前角运动神经元
DA 抑制前角运动神经元
前角后角
灰质
Dopamine theory
胆碱能神经元
多巴胺能神经元
黑质内 DA能神经元发生退行性变
出现 PD的症状
出现 PD的症状
![Page 30: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/30.jpg)
30
Dopamine theory
Ach
黑质
纹状体
DA
DA(—) ( + )
调节运动功能
脊髓前角运动神经元
![Page 31: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/31.jpg)
31
Pathogenesis
DA neuronal degeneration in substantia nigra( 黑质 )
1. Dopamine (DA) theory
↓DA synthesis
reduced or lack of dopamine in the striatum↓the function of DA in the nigro-striatal DA pathway
↑the function of Ach
muscular tension
![Page 32: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/32.jpg)
32
DA 氧化代谢
H2O2 、 O-
2
ComplexⅠ 抗氧化物(谷胱甘肽)
·OH 、 O+
2
Fe3+
促进神经膜类脂氧化
破坏 DA 神经细胞膜功能
黑质
Pathogenesis
2. Oxidative stress - free radical theory
![Page 33: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/33.jpg)
33
Treatment of Parkinson’s disease
No cure for PD Dopaminergic medication Non-dopaminergic medication Other strategies
Surgical interventionRegular exercise
![Page 34: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/34.jpg)
34
Antiparkinsonism drugs
DA
Ach
Dopaminomimetic Drugs
Central Anticholinergic Drugs
![Page 35: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/35.jpg)
35
AADC
TH: 酪氨酸羟化酶
TH
AADC:L- 芳香族氨基酸脱羧酶
![Page 36: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/36.jpg)
36
Ⅰ Dopaminomimetic Drugs
1. Precursor of DA
2. Synergetic agents of L-dopa
( 左旋多巴的增效药)3. DA receptor agonists
4. Drugs enhancing DA release
![Page 37: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/37.jpg)
37
1. Precursor of DA
—— levodopa ( L-dopa, 左旋多巴)
Levodopa Dopamine
![Page 38: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/38.jpg)
38
【 Pharmacological actions and mechanism 】
Penetrate BBB into the brain
Decarboxylated( 脱羧 ) by AADC to DA
Supply DA to striatum
![Page 39: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/39.jpg)
39
AADC
TH: 酪氨酸羟化酶
TH
AADC:L- 芳香族氨基酸脱羧酶
![Page 40: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/40.jpg)
40
【 Clinical use 】
widely used for all types of PD patients
1. Parkinson’s disease: symptomatic treatment
(1) early stage: good and stable effect
80% can be significantly improved, of which 20%
recoverd to the normal state
(2) later stage: effect gradually decreased, little effect
after 3-5 years
![Page 41: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/41.jpg)
41
Characteristics:
(1) have good effect on mild and younger patients, less
effect on severe and elderly patients
(2) more effective for musclar rigidity and akinesia ( 运
动不能 ), less effective for resting tremor, difficult to
improve the dementia( 痴呆 )
(3) slow onset, initial effective time is 2-3 w, 1-6 m to
most effective (Emax)
![Page 42: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/42.jpg)
42
(4) not effective for Parkinsonium caused by
phenothiazines( 吩噻嗪类 ) antipsychotic drugs
(5) Drug combination:
combined with peripheral AADC inhibitor,
reduce the dosage of L-DOPA by 75%
cabidopa( 卡比多巴 ) or benserazide( 苄丝肼 )
Characteristics:
![Page 43: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/43.jpg)
43
2. Hepatic coma ( 肝昏迷 ): symptomatic treatment
false neurotransmitter theory( 伪递质学说)
Levodopa metabolized to noradrenaline (NA) to replace false neurotransmitter
![Page 44: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/44.jpg)
44
食物中芳香族氨基酸 脱羧酶 酪胺和苯乙胺
肝中 MAO 清除
肠菌
肝功能
血浓度脑组织羟化酶苯乙醇胺
羟苯乙胺
拟去甲肾上腺素等递质 神经传导障碍 肝昏迷
左旋多巴 去甲肾上腺素 改善神经传导脑内转变
![Page 45: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/45.jpg)
45
【 Pharmacokinetics 】
1. Absorption
oral, absorbed by small intestine, t1/2 1-3h
Bioavailability is affected by gastric emptying,
gastric acid pH
![Page 46: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/46.jpg)
46
【 Pharmacokinetics 】
2. Distribution and metabolism
Levodopa
COMTreuptake MAO
MAO: 单胺氧化酶COMT: 儿茶酚胺 -O- 甲基转移酶
3. Elimination: kidney
—
![Page 47: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/47.jpg)
47
【 Adverse reactions 】1. early reactions :
(1) Gastrointestinal effect: 80%
anorexia( 厌食 ), nausea, vomiting
tolerance after several weeks
domperidone( 多潘立酮,吗丁啉 ) D2-R blocker
(2) Cardiovascular effects:
orthostatic hypotension ( 直立性低血压 ) 30%
arrhythmias — blocker
![Page 48: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/48.jpg)
48
【 Adverse reactions 】
2. long-term reactions
(1) Hyperkinesia( 运动过多症 , dyskinesia, 运动障碍 ):
90% ( > 2 years)
hand, feet, body — abnormal choreoathetoid movements
( 舞蹈样手足徐动症 )
over stimulation of DA-R involuntary movement ( 不自主运动 )
orofacial (triad) : sucking, licking the tongue, chewing
DA-R blocker
![Page 49: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/49.jpg)
49
(2) Fluctuations in response( 症状波动 ):
on-off phenomena
40%-80% (3-5 years)
(3) Psychic disorders
Clozapine ( 氯氮平 ) : D4
![Page 50: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/50.jpg)
50
【 Drug interactions 】
VitB6:
coenzyme of AADC, increase the activity AADC
Antipsychotic drugs:
block DA-R of Nigro-striatal system,
weaken DA function
![Page 51: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/51.jpg)
51
Levodopa: The Cornerstone of PD Therapy
Levodopa provides substantial antiparkinsonian symptom control, and significantly improves patient quality of life1
Levodopa is the most efficacious antiparkinsonian medication in moderate and advanced disease
Levodopa provides relatively rapid symptomatic benefits2,3
Levodopa is generally well tolerated with few initial side effects
Levodopa continues to provide antiparkinsonian benefits through the course of the illness
All PD patients eventually require levodopa therapy 1. Louis ED, et al. Arch Neurol. 1997;54:260-264.2. Olanow CW, et al. Neurology. 2001;56:S1-S86.3. Agidy et al. Lancet. 2002;360:575.
![Page 52: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/52.jpg)
52
2. Synergetic agents of L-dopa
( 左旋多巴的增效药)
(1)AADC ( 氨基酸脱羧酶 ) inhibitors
cabidopa, benserazide ( 苄丝肼 )
(2) MAO-B inhibitors
selegiline ( 司来吉兰 )
(3) COMT inhibitors
nitecapone ( 硝替卡朋)
![Page 53: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/53.jpg)
53
Metabolism of L-dopa
L-DOPA DAAADC
COMT3-OMD
L-DOPA
Carrier
3-OMD
DAAADC
degradation
MAO-B COMT
reuptake
( 3-O- 甲基多巴 )
BBB BrainPeriphery
![Page 54: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/54.jpg)
54
(1) AADC ( 氨基酸脱羧酶 ) inhibitors (≠BBB)
L-DOPA DAAADC
COMT3-OMD
L-DOPA
Carrier
3-OMD
DAAADC
degradation
MAO-B COMT
uptake
( 3-O- 甲基多巴 )
BBB BrainPeriphery
X
![Page 55: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/55.jpg)
55
(1) AADC ( 氨基酸脱羧酶 ) inhibitors
Carbidopa ( 卡比多巴 ) :
not penetrate BBB, only inhibit periphery AADC,
increase L-dopa into the brain,
reduce the dosage of L-dopa by 75%
Benserazide ( 苄丝肼 ): similar
Compound Preparations
Sinemet ( 息宁,心宁美 )
Levodopa : Carbidopa (10:1)
Madopar ( 美多巴 )
Levodopa : Benserazide (4:1)
![Page 56: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/56.jpg)
56
(2) MAO-B inhibitors ( = BBB)
L-DOPA DAAADC
COMT3-OMD
L-DOPA
Carrier
3-OMD
DAAADC
X
degradation
MAO-B COMT
uptake
( 3-O- 甲基多巴 )
BBB BrainPeriphery
![Page 57: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/57.jpg)
57
(2) MAO-B inhibitors- Selegiline ( 司来吉兰 )
hypertensive crisis
MAO-B: CNS (nigrostriatal)
selegiline ( 司来吉兰 ):
BBB permeable
reduce the administrated L-dopa dose and “on-off
response”
antioxidant effect
low dose ( < 10mg/d) —only inhibit MAO-B→DA↑
high dose ( > 10mg/d)—inhibit MAO-A too →
![Page 58: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/58.jpg)
58
(3) COMT inhibitors (≠or = BBB)
L-DOPA DAAADC
COMT3-OMD
L-DOPA
Carrier
3-OMD
DAAADC
X
degradation
MAO-B COMT
uptake
( 3-O- 甲基多巴 )
BBB BrainPeriphery
X
![Page 59: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/59.jpg)
59
Periphery:
CNS: DA degradation↓→ DA in CNS↑
(3) COMT inhibitors (≠or = BBB)
L-DOPA degradation↓
3-OMD (3-O- 甲基多巴 )↓
carrier available for L-DOPA↑
L-DOPA that reach the brain↑
![Page 60: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/60.jpg)
60
nitecapone ( 硝替卡朋 ): periphery
Tocapone( 托卡朋 ): periphery and CNS
Entacapone( 安托卡朋 ): periphery
(3) COMT inhibitors (≠or = BBB)
![Page 61: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/61.jpg)
61
Dopamine receptors
five main subtypes: D1 ~D5
D1-like receptors: D1, D5 excitation
D2-like receptors: D2,D3, D4 inhibition
3. DA receptor agonists
Nigro-striatal system:
D1-like receptor (D1,D5)
D2-like receptor (D2, D3)
![Page 62: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/62.jpg)
62
Bromocriptine ( 溴隐亭 ): D2 agonism ,
D1 partial antagonism
Pramipexole ( 普拉克索 ): D2 agonism
Ropinirole ( 罗平尼咯 ): D2 agonism
Lisuride ( 利修来得 ): D2 agonism,
D1 weak antagonism
3. DA receptor agonists
![Page 63: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/63.jpg)
63
Bromocriptine ( 溴隐亭 )
1. Small dose:
stimulate D2-like R in tuberoinfundibular
(结节漏斗部) reduce prolactin (PRL) and GH release
2. Large dose:
stimulate D2-like R in substantia nigro-striatal
Uses: PD, hyperprolactinemia ( 高催乳素血症 )
acromegaly ( 肢端肥大症 )
![Page 64: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/64.jpg)
64
4. Drugs enhancing DA release
Amantadine ( 金刚烷胺 ) Mechanism:
1.↑release DA from dopaminergic terminals.
2.↓reuptake of DA.
3. dopamine receptor agonism
Characteristics:
1. effect <L-DOPA but >anticholinergic agents.
2. rapid onset, last short (6-8w), synergistic
action with L-dopa
![Page 65: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/65.jpg)
Dopamine receptors
DADA
L-DOPAL-DOPA
3-OMD3-OMD
DADA
DopamineDopamineagonistsagonists
COMT COMT inhibitorsinhibitors
CarbidopaCarbidopa
MAO-BMAO-B inhibitorsinhibitors DOPACDOPAC
DA DA
3-MT3-MT
DADA
DA DA
AADCAADC
DADACOMTCOMT
inhibitor*inhibitor*
L-DOPAL-DOPA
DADADADA
Blood-brain barrierPeriphery BrainNeuron
Sites of Action of PD Drugs
*Only tolcapone inhibits COMT in brain.
L-DOPA = levodopa3-OMD = 3-O-methyldopaDA = dopamine
AADC = aromatic acid decarboxylase DOPAC = dihydroxyphenylacetic acid3-MT = 3-methoxytyramine
![Page 66: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/66.jpg)
66
Ⅱ Central Anticholinergic Drugs
![Page 67: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/67.jpg)
67
Trihexyphenidyl ( 苯海索 , artane, 安坦 )
Blocking the M-R ,↓cholinergic function in
the nigrostriatal.
Effective for Parkinsonism caused by
phenothiazines( 吩噻嗪类)
Improve the tremor of PD, little effect on
bradykinesia( 动作迟缓 ) and rigidity
![Page 68: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/68.jpg)
68
![Page 69: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/69.jpg)
69
Surgery -
Deep Brain StimulationBrain pacemaker, sends electrical impulses
to brain to stimulate the subthalamic nucleus.
Improves motor functions and reduce motor complications.
Complications include: brain hemorrhage, seizures, death.
69
![Page 70: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/70.jpg)
70
Summary
1. L-dopa is used with which drug and why?
2. Describe the classification of anti-PD drugs and their mechanism of action
![Page 71: 1 Motor systems II: The basal ganglia and Drugs used for the treatment of Parkinson’s disease Lou haiyan (娄海燕) Lou haiyan (娄海燕) Institute of Pharmacology.](https://reader035.fdocuments.net/reader035/viewer/2022081418/56649ebc5503460f94bc58c8/html5/thumbnails/71.jpg)
71